The C-terminal domain of pol II and a DRB-sensitive kinase are required for 3' processing of U2 snRNA

EMBO J. 2003 Feb 17;22(4):925-34. doi: 10.1093/emboj/cdg077.

Abstract

The human snRNA genes transcribed by RNA polymerase II (e.g. U1 and U2) have a characteristic TATA-less promoter containing an essential proximal sequence element. Formation of the 3' end of these non-polyadenylated RNAs requires a specialized 3' box element whose function is promoter specific. Here we show that truncation of the C-terminal domain (CTD) of RNA polymerase II and treatment of cells with CTD kinase inhibitors, including DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole), causes a dramatic reduction in proper 3' end formation of U2 transcripts. Activation of 3' box recognition by the phosphorylated CTD would be consistent with the role of phospho-CTD in mRNA processing. CTD kinase inhibitors, however, have little effect on initiation or elongation of transcription of the U2 genes, whereas elongation of transcription of the beta-actin gene is severely affected. This result highlights differences in transcription of snRNA and mRNA genes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • DNA Polymerase II / metabolism*
  • Dichlororibofuranosylbenzimidazole / pharmacology*
  • Enzyme Inhibitors / pharmacology*
  • Gene Expression Regulation / physiology
  • Humans
  • Protein Kinases / drug effects*
  • RNA Processing, Post-Transcriptional / physiology*
  • RNA, Small Nuclear / drug effects
  • RNA, Small Nuclear / metabolism*

Substances

  • Enzyme Inhibitors
  • RNA, Small Nuclear
  • U2 small nuclear RNA
  • Dichlororibofuranosylbenzimidazole
  • Protein Kinases
  • carboxy-terminal domain kinase
  • DNA Polymerase II